口服吲哚胺特异抑制剂1-MT治疗Lewis移植性肿瘤的实验研究  

Research on the efficacy of IDO inhibitor 1-MT on the anti-tumor effects in the Lewis lung cancer bearing mice

作　　者：欧雪玲[1] 梁伟英[2] 杜军[3] 伍新尧[1] 

机构地区：[1]中山大学中山医学院,广州510089 [2]中山大学附属第一医院黄埔院区耳鼻喉科,广州510700 [3]中山大学药学院,广东广州510089

出　　处：《解剖学研究》2008年第5期347-350,共4页Anatomy Research

基　　金：国家自然科学基金(30471978)

摘　　要：目的探讨吲哚胺(indoleamine-2,3-dioxygenase,IDO)在Lewis肺癌(Lewis lung cancer,LLC)移植性肿瘤小鼠的肿瘤组织和肿瘤引流淋巴结(tumor draining lymph nodes,TDLNs)内的表达情况,观察IDO特异性抑制剂1-甲基色氨酸(1-methyl tryptophan,1-MT)对LLC移植性肿瘤小鼠的防治作用。方法采用Western blot和免疫组化技术,分析IDO在移植性肿瘤小鼠肿瘤组织和TDLNs中的表达情况;实验分PBS对照组和1-MT治疗组,采用直接观察法与LDH释放试验检测1-MT对移植性肿瘤的发生、发展以及荷瘤宿主特异性细胞毒淋巴细胞(cytotoxic T lymphocyte,CTL)反应的影响作用。结果在LLC移植性肿瘤小鼠体内,主要是由肿瘤组织和TDLNs内的单核细胞表达IDO;实验组与PBS对照组比较,肿瘤的发生与发展延迟(P<0.05);荷瘤宿主特异性CTL反应增强(P<0.05)。结论口服1-MT可以通过特异性抑制IDO活性延迟移植性LLC的发生和发展。Objective To determine whether blocking the activity of IDO might delay the tumor development of Lewis lung cancer （LLC） and induce stronger lymph node CTL responses. Methods The IDO expression in the LLC bearing mice was detected by western blot （WB） and immunohistochemical （IHC） analysis. 24 LLC bearing mice were divided into 2 groups： the 1-MT treated group and PBS control group. The anti-tumor efficacy in diefferent treatment was determined by regular observation of tumor development and the level of lymph node cytotoxic T lymphocyte （CTL） response, which was examined by lactate dehydrogenase （LDH） release. Results In the LLC mice, IDO-positive cells were extensively accumulated in tumor draining lymph nodes （TDLNs）; Administration of 1-MT delayed the tumor development （P〈0.05 vs PBS） and inducing stronger lymph node CTL responses（P〈0.05 vs PBS）. Conclusion Inhibition of IDO activity might be required for development of cancer immunotherapy.

关 键 词：吲哚胺 1-甲基色氨酸 LEWIS肺癌 细胞毒淋巴细胞 

分 类 号：R734.2[医药卫生—肿瘤]